

MYOS Corp  
Form 10-Q  
November 08, 2013

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: September 30, 2013

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File No. 000-53298

MYOS CORPORATION  
(Exact name of registrant as specified in its charter)

Nevada  
(State or other jurisdiction of incorporation or organization)

90-0772394  
(I.R.S. Employer Identification No.)

45 Horsehill Road, Suite 106 Cedar Knolls, NJ.  
(Address of Principal Executive Offices)

07927  
(Zip Code)

(973) 509-0444  
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Edgar Filing: MYOS Corp - Form 10-Q

- Large accelerated filer
- Non-accelerated filer
- Accelerated filer
- Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes  
 No  x

As of November 8, 2013, the registrant had 111,372,282 shares of common stock outstanding.

---

---

---

INDEX	Page
<u>PART I-FINANCIAL INFORMATION</u>	2
<u>Item 1. Financial Statements</u>	2
<u>Consolidated Balance Sheets as of September 30, 2013 (unaudited) and December 31, 2012</u>	2
<u>Consolidated Statements of Operations (unaudited) for the three and nine months ended September 30, 2013 and 2012 and the period from inception (April 11, 2007) to September 30, 2013</u>	3
<u>Consolidated Statements of Changes in Stockholders' Equity (unaudited) for the period from inception (April 11, 2007) to September 30, 2013</u>	4
<u>Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2013 and 2012 and for the period from inception (April 11, 2007) to September 30, 2013</u>	5 to 6
<u>Notes to Consolidated Financial Statements</u>	7 to 21
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	22
<u>Item 3. Quantitative and Qualitative Disclosures about Market Risk</u>	25
<u>Item 4. Control and Procedures</u>	25
<u>PART II-OTHER INFORMATION</u>	
<u>Item 1. Legal Proceedings</u>	25
<u>Item 1A. Risk Factors</u>	25
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	25
<u>Item 3. Defaults Upon Senior Securities</u>	26
<u>Item 4. Mine Safety Disclosures</u>	26
<u>Item 5. Other Information</u>	26
<u>Item 6. Exhibits</u>	26
<u>SIGNATURES</u>	27



## PART 1-FINANCIAL INFORMATION

## Item 1. Financial Statements

MYOS CORPORATION AND SUBSIDIARY  
(a development stage company)  
CONSOLIDATED BALANCE SHEETS

	September 30, 2013 (Unaudited)	December 31, 2012
<b>ASSETS</b>		
Current assets		
Cash	\$1,883,464	\$3,979,662
Accounts receivable	214,740	201,579
Inventories	10,869	218,317
Prepaid expenses and other current assets	233,840	84,388
<b>Total current assets</b>	<b>2,342,913</b>	<b>4,483,946</b>
Fixed assets, net of accumulated depreciation		
Intellectual property	327,959	8,389
Intangible assets	2,000,000	2,000,000
	38,117	36,440
<b>Total assets</b>	<b>\$4,708,989</b>	<b>\$6,528,775</b>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities		
Accounts payable and accrued expenses	\$213,556	\$208,898
<b>Total current liabilities</b>	<b>213,556</b>	<b>208,898</b>
Derivatives liability	43,950	121,900
<b>Total liabilities</b>	<b>257,506</b>	<b>330,798</b>
Stockholders' equity		
Preferred stock, \$.001 par value; 25,000,000 shares authorized; no shares issued and outstanding	-	-
Common stock, \$.001 par value, 300,000,000 shares authorized; 111,372,282 shares issued and outstanding at September 30, 2013 110,033,282 shares issued and outstanding at December 31, 2012	111,372	110,033
Additional paid-in capital	16,840,133	15,733,650
Deficit accumulated during development stage	(12,500,022)	(9,645,706)
<b>Total stockholders' equity</b>	<b>4,451,483</b>	<b>6,197,977</b>
<b>Total liabilities and stockholders' equity</b>	<b>\$4,708,989</b>	<b>\$6,528,775</b>

The accompanying notes are an integral part of the financial statements



MYOS CORPORATION AND SUBSIDIARY  
(a development stage company)  
CONSOLIDATED STATEMENTS OF OPERATIONS  
(Unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,		April 11, 2007 (Inception Date) to September 30, 2013
	2013	2012	2013	2012	2013
Revenue	\$ 917,574	\$ 365,934	\$ 1,910,287	\$ 734,363	\$ 2,921,489
Cost of sales	427,431	354,590	872,188	655,997	1,785,154
Gross profit	490,143	11,344	1,038,099	78,366	1,136,335
General and administrative expenses	1,271,562	1,058,968	3,896,374	2,091,975	11,772,539
Loss from operations	(781,419 )	(1,047,624 )	(2,858,275 )	(2,013,609 )	(10,636,204 )
<b>OTHER INCOME (EXPENSE)</b>					
Interest income	847	5,561	3,969	5,561	12,445
Interest expense	(10 )	(106 )	(10 )	(802,614 )	(827,030 )
Value of warrants in excess of the amount of additional paid-in capital received in the related private placement of restricted common stock	-	-	-	-	(2,405,303 )
Change in fair value of warrants	-	229,591	-	(16,173 )	4,085,570
Impairment charge - intellectual property	-	-	-	-	(2,662,000 )
Amortization of deferred financing costs	-	-	-	(69,451 )	(80,000 )
Gain on forgiveness of debt	-	-	-	-	12,500
Total other income (expense)	837	235,046	3,959	(882,677 )	(1,863,818 )
Net loss	\$ (780,582 )	\$ (812,578 )	\$ (2,854,316 )	\$ (2,896,286 )	\$ (12,500,022 )
Weighted average number of common shares outstanding, basic and diluted	110,907,236	106,387,551	110,597,267	86,017,222	
Basic and diluted net loss per share attributable to	\$ (0.01 )	\$ (0.01 )	\$ (0.03 )	\$ (0.03 )	

common stockholders

The accompanying notes are an integral part of the financial statements

3

---

MYOS CORPORATION AND SUBSIDIARY  
(a development stage company)  
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY  
For the period from April 11, 2007 (date of inception) to September 30, 2013  
(Unaudited)

	Common Stock			Deficit accumulated during development stage	Total stockholders' equity (deficit)
	Shares	Amount \$.001 par	Additional paid-in capital		
Balance at April 11, 2007	-	\$-	\$-	\$-	\$ -
Common stock issued for cash at \$0.0002 per share	28,000,000	28,000	(23,000 )		5,000
Common stock issued for cash at \$0.004 per share	21,000,000	21,000	54,000		75,000
Net loss				(60,185 )	(60,185 )
Balance at December 31, 2007	49,000,000	49,000	31,000	(60,185 )	19,815
Net loss				(17,928 )	(17,928 )
Balance at December 31, 2008	49,000,000	49,000	31,000	(78,113 )	1,887
Net loss				(39,308 )	(39,308 )
Balance at December 31, 2009	49,000,000	49,000	31,000	(117,421 )	(37,421 )
Net loss				(16,525 )	(16,525 )
Balance at December 31, 2010	49,000,000	49,000	31,000	(133,946 )	(53,946 )
Issuance of 7,024,000 shares of Common Stock to Peak Wellness, Inc. as part of the purchase price of intellectual property	7,024,000	7,024	3,504,976		3,512,000
Fair value of shares transferred from existing stockholder to the CEO in connection with employment agreement			1,500,000		1,500,000
Proceeds from private placements of restricted common stock	8,334,997	8,335	2,472,165		2,480,500
Offering costs			(45,000 )		(45,000 )
Fair value of warrants issued to private placement investors			(2,432,365 )		(2,432,365 )
Shares issued for services	2,055,000	2,055	688,138		690,193
Vesting of options and shares issued to directors and advisory board members			360,402		360,402
Shares issued in connection with debt	400,000	400	59,600		60,000
Net loss				(5,597,300 )	(5,597,300 )
Balance at December 31, 2011	66,813,997	66,814	6,138,916	(5,731,246 )	474,484
Proceeds from private placements of restricted common stock	34,430,000	34,430	6,855,560		6,889,990
Offering costs			(178,800 )		(178,800 )
Shares issued to COO	750,000	750	(750 )		-
Shares issued to employee	10,000	10	2,690		2,700
Shares issued for services	3,423,395	3,423	451,154		454,577
Shares issued in debt conversions	2,885,550	2,885	1,343,254		1,346,139

Edgar Filing: MYOS Corp - Form 10-Q

Shares issued in exchange for warrants	1,603,673	1,604	750,579		752,183
Shares issued for exercise of warrants	116,667	117	11,550		11,667
Vesting of options and shares issued to officers, directors, advisory board members, consultants and employees			359,497		359,497
Net loss				(3,914,460 )	(3,914,460 )
Balance at December 31, 2012	110,033,282	\$ 110,033	\$ 15,733,650	\$(9,645,706 )	\$ 6,197,977
Shares issued to CEO	-	-	-		-
Shares issued to employee	1,000	1	169		170
Shares issued for services	1,338,000	1,338	177,482		178,820
Vesting of options and shares issued to officers, directors, advisory board members, consultants and employees			928,832		928,832
Net loss				(2,854,316 )	(2,854,316 )
Balance at September 30, 2013	111,372,282	111,372	16,840,133	(12,500,022)	4,451,483

The accompanying notes are an integral part of the financial statements

MYOS CORPORATION AND SUBSIDIARY  
(a development stage company)  
CONSOLIDATED STATEMENTS OF CASH FLOW  
(Unaudited)

	Nine Months Ended September 30,		11-Apr-07 (Inception Date) to September 30, 2013
	2013	2012	
<b>Cash Flows from Operating Activities</b>			
Net loss	\$(2,854,316)	\$(2,896,286)	\$(12,500,022)
Adjustments to reconcile net loss to net cash used in operating activities:			
Depreciation	25,553	771	27,002
Amortization	-	49,451	80,000
Stock based compensation	1,042,793	707,143	4,390,162
Loss on debt conversion	-	760,566	760,566
Impairment charges	-	-	2,662,000
Accounts payable paid in stock	-	7,500	-
Interest expense paid in stock	-	43,762	43,762
Related parties paid in stock	-	71,706	-
Derivatives charges and credits	22,050	(176 )	(1,521,483 )
<b>Changes in operating assets and liabilities</b>			
(Increase) decrease in accounts receivable	(13,161 )	(198,042 )	(214,740 )
(Increase) decrease in inventories	207,448	341,538	(10,869 )
(Increase) decrease in prepaid expenses and other assets	(84,425 )	87,546	(125,994 )
Increase (decrease) in accounts payable and accrued expenses	(95,342 )	(363,175 )	25,365
Net cash used in operating activities	(1,749,400)	(1,387,696)	(6,384,251 )
<b>Cash Flows from Investing Activities</b>			
Acquisition of intellectual property	-	-	(450,000 )
Acquisition of fixed assets	(345,121 )	(2,044 )	(354,959 )
Acquisition of intangible assets	(1,677 )	-	(38,117 )
Decrease in security deposits	-	10,000	-
Net cash used in investing activities	(346,798 )	7,956	(843,076 )
<b>Cash Flows from Financing Activities</b>			
(Repayments to) advances from related parties	-	-	140,434
Note borrowings	-	-	19,500
Repayment of notes payable	-	(350,000 )	(807,500 )
Proceeds from (Repayments of) issuance of notes	-	(40,500 )	540,000
Proceeds from issuance of stock to initial stockholders	-	-	80,000
Proceeds from exercise of warrants	-	11,667	11,667
Proceeds from private placement of common stock	-	6,869,990	9,350,490

Edgar Filing: MYOS Corp - Form 10-Q

Offering costs	-	(178,800 )	(223,800 )
Net cash provided by financing activities	-	6,312,357	9,110,791
Net increase/(decrease) in cash	(2,096,198)	4,932,617	1,883,464
Cash at beginning of the period	3,979,662	61,266	-
Cash at end of the period	\$1,883,464	\$4,993,883	\$1,883,464

The accompanying notes are an integral part of the financial statements

MYOS CORPORATION AND SUBSIDIARY  
(a development stage company)  
CONSOLIDATED STATEMENTS OF CASH FLOW (Continued)  
(Unaudited)

	Nine months ended September 30,		April 11, 2007 (Inception Date) to September 30, 2013
	2013	2012	
<b>Supplemental Disclosure of Cash Flow Information:</b>			
Total Cash paid for franchise taxes	\$2,650	\$2,578	\$6,028
Total Cash paid for Interest	\$10	\$15,892	\$15,902
<b>Supplemental Disclosure of Non-Cash Investing and Financing Activities:</b>			
Offering costs paid by stockholder	\$-	\$-	\$25,000
Conversion of stockholder loan and interest into common stock	\$-	\$546,743	\$549,487
Conversion of stockholder loan into capital - no shares issued	\$-	\$-	\$22,256
Conversion of 488,331 warrants into 97,669 common shares	\$-	\$44,050	\$44,050
Conversion of 7,529,999 warrants into 1,506,004 common shares	\$-	\$722,882	\$722,882
Note payable - insurance financing	\$-	\$-	\$42,500
Note issued for accounts payable	\$-	\$-	\$7,500
Acquisition of intellectual property through note payable	\$-	\$-	\$700,000
Financing costs through issuance of restricted common stock	\$-	\$20,000	\$80,000

The accompanying notes are an integral part of the financial statements

MYOS CORPORATION AND SUBSIDIARY  
(a development stage company)  
Notes to Consolidated Financial Statements  
September 30, 2013 and 2012

NOTE 1 – NATURE OF ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

Organization & Business Activities

MYOS Corporation, formerly known as Atlas Therapeutics Corporation (the "Company") was incorporated under the laws of the State of Nevada on April 11, 2007. On February 25, 2011, the Company entered into an agreement to purchase certain intellectual property from Peak Wellness, Inc. (the "Acquisition") (see Note 8 - Intellectual Property Purchase Agreement). Since the Acquisition, the Company's business focus has been on the discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies aimed at maintaining or improving the health and performance of muscle tissue. The Company has only realized revenues of \$2,921,489 through September 30, 2013 without fully implementing its plan of operations and therefore is still considered a development stage company.

Depreciation

The cost of property and equipment is depreciated over the estimated useful life of 3 to 7 years. Depreciation is computed using the straight-line method when assets are placed in service. Leasehold improvements are amortized over the lesser of the asset's useful life or the contractual remaining lease term including expected renewals.

Basis of Accounting and Principles of Consolidation

The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in accordance with generally accepted accounting principles and include the accounts of the Company and its wholly-owned subsidiary, Atlas Acquisition Corp. (formed on February 23, 2011 to facilitate the purchase of the intellectual property discussed in Note 8 - Intellectual Property Purchase Agreement). All material intercompany balances and transactions have been eliminated. These financial statements include all adjustments that, in the opinion of management, are necessary in order to make the financial statements not misleading.

Cash & Cash Equivalents

The Company considers all highly liquid investments purchased with a maturity of three months or less to be a cash equivalent.

Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period.

Fair Value of Indefinite-Lived Intangible Assets

The Company accounts for indefinite-lived intangible assets in accordance with ASC 350, Intangibles-Goodwill and Other. In accordance with ASC 350, indefinite-lived intangible assets are subject to an impairment analysis at least annually, and more frequently upon the occurrence of certain events. The impairment analysis is performed by comparing the fair value of the assets with the carrying value of the assets. Fair value is estimated as the discounted value of future revenues arising from the use of such assets. An impairment charge is recorded if the assets carrying value exceed the assets estimated fair value.

The Company's policy is to evaluate indefinite-lived intangible assets (e.g. the intellectual property) for possible impairment at least annually or whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. See Note 8 - Intellectual Property Purchase Agreement for information related to impairment charges recorded in 2011 for indefinite-lived intellectual property intangible assets.

The intellectual property carrying value as of September 30, 2013 and December 31, 2012 was \$2,000,000. Management performed their quarterly review of the intellectual property and determined no impairment existed and there was no change to the carrying value for the nine months ended September 30, 2013.

#### Revenue Recognition

The Company recognizes revenue when products are shipped and collection is reasonably assured.

MYOS CORPORATION AND SUBSIDIARY  
(a development stage company)  
Notes to Consolidated Financial Statements  
September 30, 2013 and 2012

## Inventories

Inventory consist of the following:

	September 30, 2013	December 31, 2012
Raw materials	\$ 10,869	\$ 213,848
Work in process	-	-
Finished goods	-	4,469
Total Inventory	\$ 10,869	\$ 218,317

Inventories are stated at the lower of cost or market, with cost determined on a first in, first-out basis.

## Advertising

The Company charges the costs of advertising to expense as incurred. The Company incurred \$924,368 and \$260,427 of advertising and promotional costs for the nine months ended September 30, 2013 and 2012 respectively, and \$1,518,930 since its inception. Pursuant to its distribution agreement with Maximum Human Performance (“MHP”), entered into on May 16, 2012, the Company has a co-operative advertising arrangement whereby the Company pays MHP a fee for each unit sold (See Note 10 - Commitments, Contingencies and Other Comments - Distribution Agreement).

## Fixed Assets

Fixed assets consist of the following:

	September 30, 2013	December 31, 2012
Furniture, fixtures and equipment	\$ 100,758	\$ 3,024
Computers and software	15,247	6,814
Leasehold improvements	233,954	-
Other	5,000	-
Total fixed assets	354,959	9,838
Less accumulated depreciation	(27,000)	(1,449)
Net book value of fixed assets	\$ 327,959	\$ 8,389

Repair and maintenance costs are expensed as incurred. Depreciation expense was \$25,553 and \$771 for the nine months ended September 30, 2013 and 2012, respectively.

## Concentrations of Risk, Significant Distributor and Customer and Significant Supplier

The Company maintains its bank accounts with a high credit quality financial institution and has never experienced any losses related to these bank accounts. From December 31, 2010 through December 31, 2012, all non-interest-bearing transaction accounts were fully insured by the FDIC, regardless of the balance of the account and the ownership capacity of the funds, and interest bearing accounts were insured up to \$250,000. Beginning 2013, insurance coverage reverted back to \$250,000 per depositor at each financial institution. The Company had two noninterest-bearing checking accounts and one interest-bearing savings account which totalled \$1,882,714 as of

September 30, 2013. At September 30, 2013, the Company's uninsured cash balances totalled \$1,632,714.

Effective May 2012, MHP became the exclusive distributor and sole customer of the Company's MYO-X product and formula (see Note 10 - Commitments, Contingencies and Other Comments – Distribution Agreement). MHP's exclusivity expired in September 2013. While the distribution agreement otherwise remains in effect, the parties are currently negotiating a new agreement.

The Company currently relies on one foreign company to produce the raw product for MYO-T12 (see Note 10 - Commitments, Contingencies and Other Comments – Supply Agreement). The Company is considering other supply alternatives.

#### Equity Based Compensation

The Company accounts for equity-based compensation under the provisions of ASC 718-10 Compensation - Stock Compensation and ASC 505-50 Equity Based Payments to Non-Employees. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. For stock options and restricted stock that do not vest immediately but which contain only a service vesting feature, we recognize compensation cost on the unvested shares and options on a straight-line basis over the remaining vesting period, net of any projected forfeitures

MYOS CORPORATION AND SUBSIDIARY  
(a development stage company)  
Notes to Consolidated Financial Statements  
September 30, 2013 and 2012

The Company uses the Black-Scholes option-pricing model as its method of valuation for share-based compensation. Our determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to our expected stock price volatility over the term of the awards, and certain other market variables such as the risk free interest rate.

Equity-based compensation expense for awards to employees and non-employees was \$1,042,793 and \$707,143 for the nine month periods ended September 30, 2013 and 2012, respectively.

#### Comprehensive Loss

The Company had no items of other comprehensive income or expense for the nine month periods ended September 30, 2013 and 2012. Accordingly, the Company's comprehensive loss and net loss are the same for all periods presented.

#### Research and Development

The Company incurred \$398,199 and \$18,279 of research and development costs (which are included in general and administrative expenses) for the nine months ended September 30, 2013 and 2012 respectively, and \$605,020 since its inception.

#### Segment Information

ASC 280, Disclosures about Segments of an Enterprise and Related Information, establishes standards for reporting information regarding operating segments in annual consolidated financial statements and requires selected information for those segments to be presented in financial reports issued to stockholders. It also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The Company operates in a single segment, internally reports the results of operations for that segment and the information disclosed herein materially represents all of the financial information related to the single operating segment.

#### Fair Value Measurement

The Company adopted the provisions of ASC 820 Fair Value Measurements and Disclosures on January 1, 2009. ASC 820 clarifies the principle that fair value should be based on the assumptions market participants would use when pricing an asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions. Under the standard, fair value measurements are separately disclosed by level within the fair value hierarchy. It does not require any new fair value measurements. It only applies to accounting pronouncements that already require or permit fair value measures, except for standards that relate to share-based payments.

Valuation techniques considered under ASC 820 techniques are based on observable and unobservable inputs. The ASC classifies these inputs into the following hierarchy:

Level 1 inputs are observable inputs and use quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date and are deemed to be most reliable measure of fair

value.

Level 2 inputs are observable inputs and reflect assumptions that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the reporting entity. Level 2 inputs includes 1) quoted prices for similar assets or liabilities in active markets, 2) quoted prices for identical or similar assets or liabilities in markets that are not active, 3) observable inputs such as interest rates and yield curves observable at commonly quoted intervals, volatilities, prepayment speeds, credits risks, default rates, and 4) market-corroborated inputs.

Level 3 inputs are unobservable inputs and reflect the reporting entity's own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available under the circumstances.

In October 2008, the FASB clarified the application of ASC 820 in determining the fair value of a financial asset when the market for that financial asset is not active.

The Company adopted the provisions of ASC 825, The Fair Value Option for Financial Assets and Liabilities, on January 1, 2009. ASC 825 permits us to choose to measure certain financial assets and liabilities at fair value that are not currently required to be measured at fair value (the "Fair Value Option"). Election of the Fair Value Option is made on an instrument-by-instrument basis and is irrevocable. At the adoption date, unrealized gains and losses on financial assets and liabilities for which the Fair Value Option has been elected are reported as a cumulative adjustment to beginning retained earnings.

Our intangible assets are valued and tested for impairment using Level 3 inputs (see Note 8 - Intellectual Property Purchase Agreement). In the process of the valuation of the intangible asset, we determined that the carrying cost exceeded the fair value at December 31, 2011 and we recorded an impairment charge and adjusted the balance of the asset to reflect the fair value. There were no impairment charges for any subsequent periods.

MYOS CORPORATION AND SUBSIDIARY  
(a development stage company)  
Notes to Consolidated Financial Statements  
September 30, 2013 and 2012

Basic and Diluted Income (Loss) per Share

In accordance with ASC 260, Earnings Per Share, the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding. Diluted loss per common share is computed in a manner similar to basic loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. At September 30, 2013 and 2012, the Company's stock equivalents were anti-dilutive and excluded in the diluted loss per share computation. The aggregate number of potentially dilutive options and warrants outstanding at September 30, 2013 and 2012 were 11,091,000 and 1,650,000, respectively.

Income Taxes

Income taxes are accounted for under the asset and liability method in accordance with ASC 740, Accounting for Income Taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance to the extent that the recoverability of the asset is unlikely to be recognized.

The Company follows ASC 740 rules governing uncertain tax positions, which provides guidance for recognition and measurement. This prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements. It also provides accounting guidance on recognition, classification and disclosure of these uncertain tax positions. The Company has no uncertain income tax positions.

Interest costs and penalties related to income taxes are classified as interest expense and selling, general and administrative costs, respectively, in the Company's financial statements. For the nine months ended September 30, 2013 and 2012, the Company did not recognize any interest or penalty expense related to income taxes. The Company files income tax returns in the U.S. federal jurisdiction and states in which it does business.

NOTE 2 - PRIVATE PLACEMENTS OF RESTRICTED COMMON STOCK

During April 2007, the Company sold 28,000,000 (after adjusting for the 1 to 14 split) shares of its common stock to its founders for cash proceeds of \$5,000. During December 2007, the Company sold 21,000,000 (after adjusting for the 1 to 14 split) shares of its common stock in a private placement for cash proceeds of \$75,000.

From February 25 through July 12, 2011, the Company issued an aggregate of 8,134,997 shares of common stock and warrants to purchase 8,134,997 shares of common stock to certain accredited investors (the "Private Placements") with piggy-back registration rights. Each warrant had a three-year term and was exercisable at \$0.10 per share (due to the triggering of a down round full ratchet anti dilution provision). In June and September 2012, 8,018,330 of warrants were exchanged for 1,603,673 shares of the Company's common stock and 116,667 warrants were exercised for \$11,667.

On December 2, 2011, one accredited investor purchased 200,000 shares for gross proceeds of \$40,000 in a private placement. The subscription agreement contained a "Purchase Price Protection" provision that granted the investor additional shares in the event of a private placement during the ten month period from the date of the investment at a price per share less than the investor's purchase price. The additional shares were to be issued for no additional payment such that the total per share price paid by this investor will equal the amount paid by investors in such later private placement. In April 2012, the Company issued an additional 200,000 shares to the investor as a result of the price protection provision.

During February and March 2012, the Company issued an aggregate of 10,250,000 shares of restricted common stock to certain accredited investors in a private placement and received aggregate gross proceeds of \$1,025,000. The securities are subject to piggyback registration rights.

In April 2012, the Company issued an aggregate of 1,000,000 shares of restricted common stock to one accredited investor in a private placement and received aggregate gross proceeds of \$100,000. The securities are subject to piggyback registration rights.

MYOS CORPORATION AND SUBSIDIARY  
(a development stage company)  
Notes to Consolidated Financial Statements  
September 30, 2013 and 2012

In June 2012, the Company issued an aggregate of 2,400,000 shares of restricted common stock to certain accredited investors in a private placement and received aggregate gross proceeds of \$600,000. The securities are subject to registration rights.

In July 2012, the Company issued an aggregate of 20,580,000 shares of restricted common stock to certain accredited investors in a private placement and received aggregate gross proceeds of \$5,144,990. The securities are subject to registration rights.

The Company received aggregate gross proceeds of \$9,350,490 from the private placements as follows:

Date	Shares	Gross Proceeds	Related Warrant Liability at Inception	Related Warrant Liability at September 30, 2013
February 25, 2011	4,766,666	\$ 1,430,000	\$ 2,350,251	\$ -
May 31, 2011	1,409,999	423,000	1,186,859	-
June 27, 2011	1,874,999	562,500	1,243,838	-
July 12, 2011	83,333	25,000	57,742	-
December 2, 2011	200,000	40,000	-	-
February 10, 2012	3,250,000	325,000	-	-
February 14, 2012	4,000,000	400,000	-	-
March 7, 2012	1,000,000	100,000	-	-
March 15, 2012	1,750,000	175,000	-	-
March 22, 2012	250,000	25,000	-	-
April 9, 2012	1,000,000	100,000	-	-
April 24, 2012	* 200,000	-	-	-
June 28, 2012	2,400,000	600,000	-	-
July 6, 2012	20,580,000	5,144,990	-	-
	42,764,997	\$ 9,350,490	\$ 4,838,690	\$ -

\* Shares issued under price protection provision of subscription agreement as described above.

The warrants were subject to full ratchet anti-dilution protection if the Company sold shares or share-indexed financing instruments at less than the \$0.60 exercise price. Repricing events occurred twice while the warrants were issued, once to \$0.20 on December 2, 2011 and again to \$0.10 on February 10, 2012 as a result of private placements of restricted common stock. The warrants issued in this financing arrangement did not meet the conditions for equity classification and were required to be carried as a derivative liability, at fair value. Management estimated the fair value of the warrants on the inception dates, and subsequently at each reporting period, using the Black-Scholes option-pricing model, adjusted for dilution, because that technique embodies all of the assumptions (including volatility, expected terms, dilution and risk free rates) that are necessary to determine the fair value of freestanding warrants.

On June 27, 2012, holders of an aggregate of 7,529,999 warrants exchanged those warrants for 1,506,004 shares of common stock.

On September 24, 2012, holders of an aggregate of 488,331 warrants exchanged those warrants for 97,669 shares of common stock.

On September 24, 2012, a holder of 116,667 warrants exercised those warrants at \$0.10 a share and received 116,667 shares of common stock.

#### NOTE 3 - RECENT ACCOUNTING PRONOUNCEMENTS

The Company does not believe that the adoption of any recently issued, but not yet effective, accounting standards will have a material effect on its financial position and results of operations.

#### NOTE 4 - ADVANCES, ACCOUNTS PAYABLE AND ACCRUED EXPENSES - RELATED PARTIES

As of September 30, 2013 and December 31, 2012, there are no amounts due to related parties for advances, accounts payable and accrued expenses.

MYOS CORPORATION AND SUBSIDIARY  
(a development stage company)  
Notes to Consolidated Financial Statements  
September 30, 2013 and 2012

NOTE 5 - NOTES AND LOANS PAYABLE

Convertible Notes Payable

On November 29, 2011, the Company received aggregate proceeds of \$400,000 from two individuals (\$150,000 of which was from a director of the Company) on notes payable bearing interest at 18%, due on May 29, 2012 and convertible into common stock at the rate of \$0.20 per share or an adjusted lower rate determined by reference to a subsequent qualified financing. As additional consideration, the note holders were issued an aggregate of 400,000 shares of common stock valued at \$0.15 per share for an aggregate of \$60,000. The value of the shares issued were recorded as deferred financing costs and were amortized over the six month term of the notes. There were no unamortized balances at September 30, 2013 and December 31, 2012, respectively. Related amortization expense was \$34,000 for the nine months ended September 30, 2012.

On June 28, 2012, the aggregate principal of \$400,000 and the accrued interest of \$41,800 on the notes were converted into 2,209,000 shares of restricted common stock at \$0.20 per share, the value of which exceeded the principal and accrued interest by \$618,520 on the conversion date. This amount was recorded as interest expense in the second quarter of 2012. The amount recorded as interest expense for the nine months ended September 30, 2012 was \$654,123.

Notes Payable to Director

A director loaned the Company \$99,500, of which \$60,000 was advanced on September 29, 2011 and was evidenced by an unsecured note payable which was due on October 29, 2011 bearing interest at 3%; \$10,000 was advanced in October 2011; \$10,000 was advanced in December 2011 for direct payment to a vendor and \$19,500 of which was advanced in January 2012 for direct payments to vendors. On June 28, 2012, the principal plus accrued interest on the loans and advances of \$1,961 (aggregate of \$101,461) were converted into 507,306 shares of common stock at \$0.20 per share, the value of which exceeded the principal and accrued interest by \$142,046 on the conversion date. This amount was recorded as interest expense in the second quarter of 2012. The amount recorded as interest expense for the nine months ended September 30, 2012 was \$143,557.

Note Payable to Shareholders

On May 20, 2010, the Company issued a note for \$7,500 bearing interest at 5% in exchange for a shareholder's payment of \$7,500 on an open account payable balance. The note was due and payable upon demand. On September 20, 2012, the aggregate principal and accrued interest were converted into 30,000 shares of restricted common stock. The amount recorded as interest expense for the nine months ended September 30, 2012 was \$188.

On June 15, 2012, a stockholder loaned the Company \$65,000, payable on July 15, 2012 without interest. The loan was repaid in July 2012.

NOTE 6 - CAPITAL STOCK

On February 12, 2010, the Company's articles of incorporation were amended to increase the number of authorized preferred shares to 25,000,000 and the number of authorized common shares to 300,000,000. The Company's 3,500,000 common shares outstanding were also forward split on a 14 shares for 1 basis with the result that 49,000,000 shares were issued and outstanding on that date. The accompanying financial statements reflect the forward stock split on a retroactive basis.

NOTE 7 - WARRANTS, OPTIONS, EQUITY INCENTIVE PLAN AND STOCK ISSUANCES

Warrants

During the year ended December 31, 2011, the Company issued a total of 8,284,997 warrants to purchase restricted common stock. Of those warrants, 8,134,997 were issued to private placement investors and included down round full ratchet anti-dilution provisions requiring periodic repricing if shares are later offered at lower prices. In June 2012, holders of 7,529,999 warrants received 1,506,004 shares of restricted common stock in exchange for those warrants. In September 2012, holders of 488,331 warrants received 97,669 shares of restricted common stock in exchange for such warrants and a holder of 116,667 warrants exercised such warrants at \$0.10/share and received 116,667 shares of restricted common stock. During the year ended December 31, 2012 and nine months ended September 30, 2013, no warrants were issued.

MYOS CORPORATION AND SUBSIDIARY  
(a development stage company)  
Notes to Consolidated Financial Statements  
September 30, 2013 and 2012

The following table summarizes the total warrants issued to private placement investors and consultants. During the nine months ended September 30, 2013, no warrants were issued. Derivative charges were \$22,050 and (\$177) for the nine months ended September 30, 2013 and 2012, respectively. The number of warrants outstanding as of September 30, 2013 is 50,000.

Grant Date	Number of Warrants Issued	Number of Warrants Exchanged, Exercised or Expired	Number of Warrants Outstanding as of September 30, 2013	Exercise Price Original/Repriced	Expiration Term in Years
February 25, 2011 (A)	4,766,666	4,766,666	-	\$ 0.60/\$0.10	-
May 31, 2011 (A)	1,409,999	1,409,999	-	\$ 0.60/\$0.10	-
June 27, 2011 (A)	1,874,999	1,874,999	-	\$ 0.60/\$0.10	-
June 27, 2011 (B)	100,000	100,000	-	\$ 1.00	-
July 12, 2011 (A)	83,333	83,333	-	\$ 0.60/\$0.10	-
December 23, 2011 (B)	50,000	-	50,000	\$ 1.00	.23

(A) Private placement warrants (these warrants were subject to down round full ratchet anti dilution provisions and the exercise price was adjusted to \$0.10 per share in February 2012)

(B) Sponsorship agreement, including put option - see Note 10 - Commitments, Contingencies and Other Comments – Sponsorship Agreement.

The following table summarizes the activities in warrants for the year ended December 31, 2012 and the nine months ended September 30, 2013:

	Shares Under Warrants	Weighted Average Exercise Price Original/Repriced
Balance at January 1, 2012	8,284,997	\$ 0.61/\$0.10
Warrants granted	-	
Warrants exercised	(116,667)	
Warrants cancelled/exchanged/expired	(8,018,330)	
Balance at December 31, 2012	150,000	\$ 1.00
Warrants granted	-	
Warrants exercised	-	
Warrants cancelled/exchanged/expired	100,000	\$ 1.00
Balance at September 30, 2013	50,000	\$ 1.00

The following table summarizes information about warrants outstanding and exercisable at September 30, 2013. As all warrants currently outstanding are fully and immediately vested at issuance, the information for both outstanding and exercisable are identical.

Warrants Outstanding and Exercisable

Edgar Filing: MYOS Corp - Form 10-Q

Range of Exercise Price	Warrants Outstanding and Exercisable	Weighted Average Remaining Contractual Life
\$ 1.00	50,000	.23

The following table summarizes the assumptions used to value the warrants using the Black-Scholes option pricing model:

Grant Date	Number of Warrants Issued/ Outstanding	Stock Price on Measurement Date	Exercise Price	Expected Term	Expected Volatility	Dividend Yield	Risk Free Rate
(A) 02/25/11	4,766,666	\$ 0.50	\$ 0.60	3.00	285.20%	0.00%	1.48%
(A) 05/31/11	1,409,999	\$ 0.85	\$ 0.60	3.00	208.89%	0.00%	0.79%
(A) 06/27/11	1,874,999	\$ 0.67	\$ 0.60	3.00	295.31%	0.00%	0.64%
(A) 07/12/11	83,333	\$ 0.70	\$ 0.60	3.00	278.00%	0.00%	0.42%
(B) 06/27/11	100,000	\$ 0.67	\$ 1.00	2.00	213.59%	0.00%	0.41%
(B) 12/23/11	50,000	\$ 0.09	\$ 1.00	2.00	209.00%	0.00%	0.28%

(A) Private placement warrants

(B) Sponsorship agreement, including put option - see Note 10 - Commitments, Contingencies and Other Comments – Sponsorship Agreement.

MYOS CORPORATION AND SUBSIDIARY  
(a development stage company)  
Notes to Consolidated Financial Statements  
September 30, 2013 and 2012

## Options

The Company has issued an aggregate of 1,500,000 options to purchase restricted common stock to certain directors and scientific advisory board members (see Note 10 - Commitments, Contingencies and Other Comments – Director Agreements) prior to the adoption of the 2012 Equity Incentive Plan (the “Plan”). For options issued under the Equity Incentive Plan, see “Equity Incentive Plan” below.

The following table summarizes the activities in stock options (outside the Plan) for the year ended December 31, 2012 and the nine months ended September 30, 2013:

	Shares Under Options	Weighted Average Exercise Price
Balance at January 1, 2012	1,250,000	\$ 0.61
Options granted	250,000	\$ 0.14
Options exercised	-	
Options cancelled/expired	-	
Balance at December 31, 2012	1,500,000	\$ 0.53
Options granted	-	
Options exercised	-	
Options cancelled/expired	-	
Balance at September 30, 2013	1,500,000	\$ 0.53

At September 30, 2013, the weighted-average remaining term of the options was 7.95 years. As of September 30, 2013, the aggregate intrinsic value of outstanding options and the aggregate intrinsic value of exercisable options was \$NIL. The aggregate intrinsic value is calculated by multiplying the number of outstanding and exercisable options by the amount by which the market price for our common stock at September 30, 2013 would exceed the exercise price for each option. The market price for our common stock at September 30, 2013 was \$0.12. The aggregate unvested cost of the options at September 30, 2013 was \$79,861.

The following table summarizes the assumptions used to value the director/advisory board options using the Black-Scholes option pricing model:

Grant Date	Number of Options	Stock Price on Measurement Date	Exercise Price	Expected Term	Expected Volatility	Dividend Yield	Risk Free Rate
07/14/11	750,000	\$ 0.64	\$ 0.64	10.00	287.00%	0.00%	2.98%
07/26/11	250,000	\$ 0.69	\$ 0.69	10.00	285.00%	0.00%	2.99%
08/15/11	250,000	\$ 0.45	\$ 0.45	10.00	284.00%	0.00%	2.29%
05/24/12	250,000	\$ 0.14	\$ 0.14	10.00	187.00%	0.00%	1.77%

MYOS CORPORATION AND SUBSIDIARY  
(a development stage company)  
Notes to Consolidated Financial Statements  
September 30, 2013 and 2012

The following table summarizes information about the options (outside the Plan) outstanding and exercisable at September 30, 2013 by the directors and scientific advisory board members:

Options Outstanding			Options Exercisable		
Range of Exercise Price	Options Outstanding	Weighted Average Remaining Contractual Life	Range of Exercise Price	Options Exercisable	Weighted Average Remaining Contractual Life
\$ 0.64	750,000	7.79	\$ 0.64	625,000	7.79
\$ 0.69	250,000	7.82	\$ 0.69	250,000	7.82
\$ 0.45	250,000	7.87	\$ 0.45	250,000	7.87
\$ 0.14	250,000	8.65	\$ 0.14	166,666	8.65

As of September 30, 2013, 1,291,666 options have vested and 208,334 options remain unvested. The vesting terms range from 3 to 4 years and the vested options have a weighted average remaining term of 7.92 years and a weighted average exercise price of \$0.55 per share.

#### Equity Incentive Plan

On September 24, 2012, the Company's board of directors adopted the 2012 Equity Incentive Plan (the "Plan"), which was adopted by stockholders on November 20, 2012. The Company believes that such awards better align the interests of its employees and directors with those of its shareholders. The Company has reserved 10,000,000 shares of common stock under the Plan. As of September 30, 2013, options to purchase 9,541,000 shares of the Company's stock have been granted under the Plan, as set forth in the table below:

Issued to	Number of Options	Range of Exercise Price	Expiration Term in Years
Employees	112,000	\$ 0.20 to 0.25	10
Consultants	1,327,000	\$ 0.20 to 0.25	10
Officers	1,152,000	\$ 0.20 to 0.25	10
Directors	6,700,000	\$ 0.14 to 0.35	10
Scientific Advisory Board Member	250,000	\$ 0.25	10
Total	9,541,000		

The fair value of each option award is estimated on the date of grant using a Black Scholes model that uses variables noted in the following table. Our determination of fair value is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to our expected stock price volatility over the term of the awards, and certain other market variables such as the risk free interest rate.

The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury 10-year note in effect at the time of the grant.

The following table summarizes the assumptions used to value the Plan options using the Black-Scholes option pricing model:

Grant Date	Number of Options	Stock Price on Measurement Date	Exercise Price	Expected Term	Expected Volatility	Dividend Yield	Risk Free Rate
11/20/12	6,000	\$ 0.20	\$ 0.20	10.00	166.00%	0.00%	1.66%
01/01/13	150,000	\$ 0.19	\$ 0.22	10.00	164.00%	0.00%	2.00%
01/07/13	350,000	\$ 0.20	\$ 0.20	10.00	166.00%	0.00%	1.92%
01/07/13	2,000,000	\$ 0.20	\$ 0.25	10.00	166.00%	0.00%	1.92%
02/07/13	5,000,000	\$ 0.20	\$ 0.35	10.00	164.00%	0.00%	1.99%
02/07/13	450,000	\$ 0.20	\$ 0.25	10.00	164.00%	0.00%	1.99%
02/08/13	250,000	\$ 0.19	\$ 0.20	10.00	164.00%	0.00%	2.00%
02/28/13	100,000	\$ 0.20	\$ 0.25	10.00	158.00%	0.00%	1.89%
04/01/13	150,000	\$ 0.14	\$ 0.14	10.00	160.00%	0.00%	1.86%
05/06/13	400,000	\$ 0.12	\$ 0.25	10.00	161.00%	0.00%	1.80%
05/20/13	10,000	\$ 0.12	\$ 0.25	10.00	161.00%	0.00%	1.97%
05/21/13	200,000	\$ 0.12	\$ 0.25	10.00	161.00%	0.00%	1.94%
05/24/13	5,000	\$ 0.13	\$ 0.25	10.00	160.00%	0.00%	2.01%
06/10/13	100,000	\$ 0.16	\$ 0.25	10.00	160.00%	0.00%	2.22%
07/01/13	150,000	\$ 0.19	\$ 0.19	10.00	159.00%	0.00%	2.50%
08/21/13	220,000	\$ 0.17	\$ 0.25	10.00	157.00%	0.00%	2.87%

## MYOS CORPORATION AND SUBSIDIARY

(a development stage company)

Notes to Consolidated Financial Statements

September 30, 2013 and 2012

The following table summarizes the activities in stock options issued under the Plan during 2012 and during the nine month period ended September 30, 2013:

	Shares Under Options	Weighted Average Exercise Price
Balance at January 1, 2012	-	
Options granted	8,000	\$ 0.20
Options exercised	-	
Options cancelled/expired	-	
Balance at December 31, 2012	8,000	\$ 0.20
Options granted	9,535,000	\$ 0.30
Options exercised	-	
Options cancelled/expired	(2,000)	\$ 0.20
Balance at September 30, 2013	9,541,000	\$ 0.30

At September 30, 2013, the weighted-average remaining term of the options was 9.38 years. As of September 30, 2013, the aggregate intrinsic value of outstanding options and the aggregate intrinsic value of exercisable options was \$NIL. The aggregate intrinsic value is calculated by multiplying the number of outstanding and exercisable options by the amount by which the market price for our common stock at September 30, 2013 would exceed the exercise price for each option. The market price for our common stock at September 30, 2013 was \$0.12. The aggregate unvested cost of the options at September 30, 2013 was \$1,116,174.

The following table summarizes information about options outstanding and exercisable at September 30, 2013 that were granted under the Plan:

Options Outstanding			Options Exercisable		
Range of Exercise Price	Options Outstanding	Weighted Average Remaining Contractual Life	Range of Exercise Price	Options Exercisable	Weighted Average Remaining Contractual Life
\$ 0.14	150,000	9.51	\$ 0.14	-	-
\$ 0.19	150,000	9.76	\$ 0.19	-	-
\$ 0.20	606,000	9.31	\$ 0.20	159,333	9.32
\$ 0.22	150,000	9.28	\$ 0.22	-	-
\$ 0.25	3,485,000	9.40	\$ 0.25	358,332	9.29
\$ 0.35	5,000,000	9.36	\$ 0.35	-	-

As of September 30, 2013, 517,665 options have vested and 9,023,335 options remain unvested. The vesting terms range from zero to 5 years and the vested options have a weighted average remaining term of 9.30 years and a weighted average exercise price of \$0.23 per share.

#### Stock Issuances

During the year ended December 31, 2012, the Company issued an aggregate of 4,183,395 shares of restricted common stock to consultants, a director, an employee and officers for services provided to the Company. The shares issued were valued at trading prices on the date of issuance between \$0.07 and \$0.45 per share. The compensation cost as a result of the issuance and vesting of such shares are aggregate charges of \$40,337 and \$445,063 for the nine month periods ended September 30, 2013 and 2012, respectively. The shares issued to one of our officers and a director are subject to certain vesting requirements.

During the nine months ended September 30, 2013, the Company issued an aggregate of 1,339,000 shares of restricted common stock to a director, an employee and consultants. All such shares were valued at trading prices on the date of issuance between \$0.12 and \$0.20 per share. The compensation cost as a result of the issuance and vesting of such shares is an aggregate charge of \$94,549 for the nine month period ended September 30, 2013. Additionally, on January 7, 2013, the Company issued 5,000,000 shares to an officer which were subsequently cancelled in April 2013 upon the termination of his employment with the Company.

MYOS CORPORATION AND SUBSIDIARY  
(a development stage company)  
Notes to Consolidated Financial Statements  
September 30, 2013 and 2012

NOTE 8 – INTELLECTUAL PROPERTY PURCHASE AGREEMENT

On February 25, 2011, the Company, Atlas Acquisition Corp., a wholly-owned subsidiary of the Company formed in February 2011 (“Atlas Sub”), and Peak Wellness, Inc. (“Peak”), entered into and consummated an Intellectual Property Purchase Agreement (the “Purchase Agreement”), pursuant to which Atlas Sub purchased certain intellectual property assets from Peak (the “Acquisition”). Pursuant to the Purchase Agreement, the Company acquired from Peak all intellectual property pertaining to MYO-T12, a natural-myostatin inhibitor, including the formula and process for making MYO-T12, certain trademarks, trade secrets, patent applications and certain domain names. The aggregate consideration for MYO-T12 was \$4,662,000 paid in cash, a promissory note and shares of common stock. The contractually stated purchase price for the assets was \$1,150,000, of which \$450,000 was paid in cash and \$700,000 via the issuance of the promissory note. Additionally, the Company issued 7,024,000 shares of common stock with an aggregate fair value of \$3,512,000 to Peak as part of the purchase price of MYO-T12, representing 12% of the fully diluted voting common stock of the Company on the date of the Acquisition.

In connection with the Purchase Agreement, the Company issued a secured promissory note to Peak (the “Promissory Note”) in the amount of \$700,000 with interest accruing at an interest rate of 3% per annum. The Promissory Note was payable in two installments as follows: \$350,000 plus accrued interest was due within 180 days after the closing date of the Agreement (originally August 25, 2011 but extended to the earlier of November 30, 2011 or the closing of a certain financing and paid on November 29, 2011) and \$350,000 plus accrued interest was due on the first anniversary of the closing date of the Agreement and paid on February 21, 2012.

In connection with the Purchase Agreement and the Promissory Note, the Company entered into a security agreement with Peak to secure the payments due under the Promissory Note (the “Security Agreement”). Pursuant to the Security Agreement, the Company granted Peak a continuing security interest in the assets purchased from Peak. The Security Agreement also secured all of the Company’s obligations to Peak, whether related or unrelated to the Promissory Note. The security interest was released in February 2012 upon payment of the final installment of the Promissory Note. On the closing date of the Acquisition, new officers and a new director were appointed to serve the Company.

The Company completed its first annual impairment testing for indefinite-lived intangible assets after the fourth quarter of 2011. Based on (i) assessment of current and expected future economic conditions, (ii) trends, strategies and projected revenues from sales of MYO-T12 and (iii) assumptions similar to those that market participants would make in valuing the Company's intangible assets, management determined that the carrying values of the intellectual property intangible assets exceeded its fair value. Accordingly, the Company recorded noncash impairment charges totaling \$2,662,000 in 2011, reducing the MYO-T12 intellectual property asset to its fair value of \$2,000,000.

The intellectual property carrying value as of September 30, 2013 and December 31, 2012 was \$2,000,000. Management performed their annual and quarterly reviews of the intellectual property and determined no impairment existed and there was no change to the carrying value for the year ended December 31, 2012 and the nine months ended September 30, 2013, respectively.

NOTE 9 - INCOME TAXES

Income tax expense for the nine months ended September 30, 2013 and 2012 is shown as follows:

Edgar Filing: MYOS Corp - Form 10-Q

Nine months ended September 30,	2013	2012
Current	\$ 1,300	\$ 1,550
Deferred	-	-
Total	\$ 1,300	\$ 1,550

17

---

MYOS CORPORATION AND SUBSIDIARY  
(a development stage company)  
Notes to Consolidated Financial Statements  
September 30, 2013 and 2012

The effects of temporary differences between the financial reporting and income tax bases of assets and liabilities which give rise to the deferred tax assets and liabilities are presented below:

	September 30, 2013	December 31, 2012
Deferred tax assets:		
Goodwill	\$ 588,015	\$ 672,348
Net operating losses	3,104,230	2,133,004
Other	1,582	1,542
Total deferred tax assets	3,693,827	2,806,894
Valuation allowance	(3,681,438)	(2,804,632)
Total net deferred tax assets	12,389	2,262
Deferred tax liabilities:		
Depreciation	(12,389)	(2,262)
Total deferred tax liabilities	(12,389)	(2,262)
Net deferred tax asset	\$ -	\$ -

The valuation allowance for the deferred tax asset increased by \$876,806 for the nine months ended September 30, 2013.

The Company has net operating losses amounting to approximately \$7,891,134 that expire in various periods through 2033. The ultimate realization of the net operating losses is dependent upon future taxable income, if any, of the Company and may be limited in any one period by alternative minimum tax rules. Although management believes that the Company will have sufficient future taxable income to absorb the net operating loss carryovers before the expiration of the carryover period, the current global economic crisis imposes additional profitability risks that are beyond the Company's control. Accordingly, management has determined that a full valuation allowance of the deferred tax asset is appropriate at this time.

Internal Revenue Code Section 382 imposes limitations on the use of net operating loss carryovers when the stock ownership of one or more 5% shareholders (shareholders owning 5% or more of the Company's outstanding capital stock) has increased by more than 50 percentage points. Management intends to carefully monitor share ownership of 5% shareholders but cannot control the ownership changes occurring as a result of public trading of the Company's Common Stock. Accordingly, there is a risk of an ownership change beyond the control of the Company that could trigger a limitation of the use of the loss carryover.

The Company has no uncertain income tax positions.

The tax years ended December 31, 2007 through 2012 are open for examination by federal and state taxing authorities.

The statutory federal income tax rate and the effective rate are reconciled as follows:

Edgar Filing: MYOS Corp - Form 10-Q

	September 30, 2013	September 30, 2012
Statutory federal income tax rate	34.00%	34.00%
State taxes, net of federal tax benefit	5.94%	5.00%
Valuation allowance	(39.94)%	(39.00)%
Net deferred tax asset	-%	-%

MYOS CORPORATION AND SUBSIDIARY  
(a development stage company)  
Notes to Consolidated Financial Statements  
September 30, 2013 and 2012

## NOTE 10 - COMMITMENTS, CONTINGENCIES AND OTHER COMMENTS

## Distribution Agreement

On May 16, 2012, the Company entered into a distribution agreement (the "Agreement") with MHP, a company engaged in the development, marketing and distribution of nutritional and other therapies for the consumer. Pursuant to the Agreement, MHP will, on an exclusive basis, provide marketing, sales and distribution of MYO-T12, to be sold under the brand name MYO-X, in retail and other outlets. MHP agreed to pay the Company \$195,301 upon the execution of the Agreement, with such amount credited against inventory purchases. The Agreement also provides, upon termination of MHP's exclusivity rights, additional supply and payment rights to MHP (including a per-unit royalty in the low single digits). The Agreement provided for one year of exclusivity for MHP, which expired on September 29, 2013. While the Agreement remains in effect, the parties are currently negotiating a new agreement. The Agreement further provides for a co-operative advertising arrangement with MHP, whereby the Company is required to pay MHP a fee for each unit of MYO-X sold, and rebate payments to MHP based on a percentage of product cost reductions realized by the Company.

## Bank Line of Credit

In October 2013, the Company was granted a \$500,000 line of credit by City National Bank, that bears a per annum interest rate through April 15, 2014 equal to the prime rate, after which the rate changes to the prime rate plus 1.25 percent. As of the date of this report, the Company has not drawn on the line of credit.

## Operating Lease

The Company leases its corporate offices under an operating lease expiring in July 2017. The Company has two options to renew such lease for a term of three years each with annual rent increases of 3%.

The future minimum lease payments under the non-cancellable operating lease in excess of one year at September 30, 2013 is as follows:

Year Ending December 31,	Amount
2013	\$ 14,042
2014	59,434
2015	65,095
2016	67,163
2017	39,623
Total	\$ 245,357

Rent expense for the nine months ended September 30, 2013 and 2012 was \$44,018 and \$22,155, respectively.

## Supply Agreement

On June 24, 2013, the Company entered into a supply agreement with Deutsches Institut für Lebensmitteltechnik e.V. - the German Institute for Food Technologies ("DIL"). The agreement obligates the Company to minimum annual quantity purchases, and provides that DIL will manufacture and supply the Company with the proprietary product contained in MYO-X and that DIL shall only manufacture the product for commercial purposes with the Company's consent. The term of the agreement is for two years, and will continue indefinitely until terminated by either party upon three months written notice.

## Employment Agreements

### J.B. Bernstein:

On February 25, 2011, the Company entered into an employment agreement with J.B. Bernstein, pursuant to which Mr. Bernstein served as Chief Executive Officer of the Company. The employment agreement was amended effective as of March 1, 2011. On April 30, 2012, J.B. Bernstein resigned from his positions as President and Chief Executive Officer and as a member of the Company's board of directors. In connection with his resignation, Mr. Bernstein entered into a consulting agreement with the Company (the "Consulting Agreement"), pursuant to which Mr. Bernstein was entitled to a consulting fee of \$5,000 per month during the six-month term of the Consulting Agreement, which expired on October 31, 2012. The Consulting Agreement also included confidentiality and non-competition obligations and provisions for intellectual property assignments by Mr. Bernstein.

### Carlton Colker MD, FACN:

On February 25, 2011, concurrent with the closing of the Acquisition, the Company entered into an employment agreement with Carlton Colker, MD, FACN, pursuant to which Dr. Colker agreed to serve as Chief Medical Officer and Executive Vice President of the Company. On June 14, 2012, Dr. Carlton Colker resigned from his positions as Chief Medical Officer and Executive Vice President. Simultaneously with his resignation, Dr. Colker agreed to serve on the Company's Scientific Advisory Board. In connection with his appointment to the Scientific Advisory Board, Dr. Colker entered into an advisory board agreement with the Company, pursuant to which the Company issued him 300,000 shares of common stock. The Agreement also includes standard confidentiality and non-competition obligations and provisions for intellectual property assignments by Dr. Colker.

MYOS CORPORATION AND SUBSIDIARY  
(a development stage company)  
Notes to Consolidated Financial Statements  
September 30, 2013 and 2012

Glen R. Fleischer:

On January 2, 2013, we entered into an employment agreement with Glen R. Fleischer pursuant to which Mr. Fleischer agreed to serve as our Chief Executive Officer and as a member of our board of directors.

Pursuant to the terms of the agreement, Mr. Fleischer would work for us on a full-time basis and receive an annual base salary of \$320,000. Mr. Fleischer was also entitled to an annual cash bonus in an amount up to 100% of his base salary, as determined by our board of directors in its sole discretion. In addition, Mr. Fleischer was granted 5,000,000 shares of our common stock, which shares were to vest in four equal semi-annual installments commencing on July 2, 2013. The term of the agreement was three years, and the agreement was to automatically renew for successive one-year periods, unless a notice of non-renewal was provided by either party at least sixty days prior to the expiration date of the term. On April 25, 2013, Mr. Fleischer resigned as our Chief Executive Officer and as a member of our board of directors.

Peter A. Levy:

On February 8, 2013, we entered into an amended and restated employment agreement with Peter Levy to continue to serve as our Chief Operating Officer and Executive Vice President. The agreement replaced Mr. Levy's existing employment agreement dated February 10, 2012. Pursuant to the terms of the agreement, Mr. Levy will continue to work as Chief Operating Officer and Executive Vice President on a full-time basis and receive an annual base salary of \$200,000. Mr. Levy may receive an annual cash bonus in an amount up to 100% of his base salary, as may be determined by the Board in its sole discretion. The 500,000 shares of common stock previously granted to Mr. Levy will vest in four equal semi-annual installments commencing on August 10, 2012. The term of the agreement is three years, and the agreement will automatically renew for successive one-year periods, unless a notice of non-renewal is provided by either party at least sixty days prior to the expiration date of the term.

In the event Mr. Levy's employment is terminated for cause (as defined in the agreement) or as a result of death or disability, or if Mr. Levy terminates his employment without good reason (as defined in the agreement), Mr. Levy will be entitled to receive any accrued and unpaid base salary and employee benefits up to the date of termination as well as retain any shares that have previously vested.

In the event Mr. Levy's employment is terminated for any reason other than cause, death or disability, or if Mr. Levy terminates his employment for good reason, he will be entitled to receive any accrued and unpaid base salary and employee benefits up to the date of termination as well as any vested shares. In addition, he will be entitled to receive his base salary for twelve months following the date of termination, a cash amount equal to the greater of (i) \$50,000 or (ii) the average of all annual cash bonuses received under the agreement, and payment of all COBRA premiums for twelve months following the date of termination.

In the event Mr. Levy's employment is terminated in connection with, or as a result of, a change of control (as defined in the agreement), or if Mr. Levy terminates his employment for good reason following a change in control, he will be entitled to receive any accrued and unpaid base salary and employee benefits up to the date of termination. In addition, he will be entitled to receive his base salary for twelve months following the date of termination, a cash amount equal to the greater of (i) \$50,000 or (ii) the average of all annual cash bonuses received under the agreement, and payment of all COBRA premiums for twelve months following the date of termination. Furthermore, all of his unvested shares will vest as of the date of the consummation of the change in control.

The agreement contains customary non-competition and non-solicitation provisions that extend to two years after termination of Mr. Levy's employment. Mr. Levy also agreed to customary terms regarding confidentiality and ownership of product ideas.

On April 21, 2013, Mr. Levy was appointed to the additional position of President of the Company and in such capacity will serve as the Company's Principal Executive Officer.

#### Sponsorship Agreement

On June 27, 2011, the Company entered into a one year agreement with a celebrity spokesperson pursuant to which the spokesperson agreed to perform certain services for the Company and granted the Company the worldwide right to use the spokesperson's name and approved image in various media. The agreement provided for cash compensation of \$150,000 in three equal installments of \$50,000, all of which was paid in 2011. Royalties at the rate of \$0.50 per unit sold are payable to the spokesperson for the term of the agreement and an additional 12 months thereafter. The agreement expired in June 2012.

MYOS CORPORATION AND SUBSIDIARY  
(a development stage company)  
Notes to Consolidated Financial Statements  
September 30, 2013 and 2012

The agreement also provided for the issuance of warrants to purchase 150,000 shares of common stock, 100,000 of which were issued upon signing of the agreement and 50,000 of which were issued in December 2011. The warrants have a term of two years with an exercise price of \$1.00 per share. The warrants further provide that in the event (a) the trading price of the common stock of the Company on its principal trading market does not exceed \$2.00 within two years of issuance and (b) the warrants are not exercised prior to such time, then the spokesperson shall have the right to sell any unexercised portion of the warrants to the Company in exchange for \$1.00 for each share of common stock underlying the unexercised portion of the warrants.

The 100,000 warrants issued upon execution of the agreement and the 50,000 warrants issued in December 2011 were valued at September 30, 2013 at \$NIL and \$43,950, respectively, using a Black-Scholes option pricing model with the put option as the predominant feature of the instrument. On June 27, 2013, the 100,000 warrants expired and a \$100,000 liability was recorded.

#### Director Agreements

##### Dr. Louis Aronne:

On July 14, 2011, the Company entered into two separate agreements with Dr. Louis Aronne to be a member of the Board of Directors and the Scientific Advisory Board. The director agreement provides for compensation in the form of 100,000 shares of restricted common stock vesting in five equal annual installments commencing on execution of the agreement and an option to purchase 250,000 shares of common stock at an exercise price of \$0.64 for 10 years vesting over a period of 3 years, the first installment of which vested immediately. Upon a Change of Control, the unvested shares and the option will vest immediately. The advisory board agreement has a term of 5 years and provides for the issuance of 500,000 shares vesting in five equal annual installments commencing July 14, 2012 and an option to purchase 500,000 shares at \$.64 per share vesting in four equal annual installments, and the first installment vested immediately upon the execution of the agreement. Upon a Change of Control, all unvested option shall immediately vest.

##### Dr. Robert Hariri:

On July 26, 2011, the Company entered into an agreement with Dr. Robert Hariri to be a member of the Board of Directors. The director agreement provides for 100,000 shares of restricted common stock vesting in five equal annual installments (the first installment of which vested immediately) and an option to purchase 250,000 shares of common stock at an exercise price of \$0.69 for 10 years vesting over a period of 3 years, the first installment of which vested immediately. Upon a Change of Control, the unvested shares and the option shall immediately vest.

##### Dr. Peter Diamandis:

On August 15, 2011, the Company entered into an agreement with Dr. Peter Diamandis to be a member of the Board of Directors. The director agreement provides for 100,000 shares of restricted common stock vesting in five equal annual installments (the first installment of which vested immediately) and an option to purchase 250,000 shares of common stock at an exercise price of \$0.45 for 10 years vesting over a period of 3 years, the first installment of which vested immediately. Upon a Change of Control, the unvested shares and the option shall immediately vest.

##### Dr. Buzz Aldrin:

On May 24, 2012, the Company entered into an agreement with Dr. Buzz Aldrin to be a member of the Board of Directors. The director agreement provides for 100,000 shares of restricted common stock vesting in five equal

annual installments (the first installment of which vested immediately) and an option to purchase 250,000 shares of common stock at an exercise price of \$0.14 for 10 years vesting over a period of 3 years, the first installment of which vested immediately. Upon a Change of Control, the unvested shares and the option shall immediately vest.

Dr. Sapna Srivastava:

On February 6, 2013, the Company entered into an agreement with Dr. Sapna Srivastava to serve as a member of the Board of Directors. The director agreement provides for the issuance of 100,000 shares of restricted common stock, vesting in five equal annual installments (the first installment of which vested immediately) and an option to purchase 250,000 shares of common stock, issued under the Plan, at an exercise price of \$0.20 for 10 years vesting over a period of 3 years. The options are subject to the terms and provision of the Plan.

NOTE 11 - SUBSEQUENT EVENTS

NONE

Item Management's Discussion and Analysis of Financial Condition and Results of Operations.

2.

The following discussion should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and related notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2012.

Certain statements in this section contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this report and not clearly historical in nature are forward-looking, and the words "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "projects," "predicts," "intends," "potential," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) generally are intended to identify forward-looking statements. Any statements in this report that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

#### Overview

We were incorporated in the State of Nevada on April 11, 2007. Prior to February 26, 2011, we did not have any operations and did not generate any revenues. In February 2011, we acquired our platform dietary supplement product called MYO-T12. Since February 2011, our principal activities have been focused on the discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies aimed at maintaining or improving the health and performance of muscle tissue. We are focused on maximizing revenues from MYO-T12 in a consumer base of body builder and fitness users as well as a broader target of wellness focused baby boomers. Additionally, we are evaluating the value of MYO-T12 in therapeutic markets, including the treatment of muscular-related conditions, including age-related muscle loss and sarcopenia.

#### Plan of Operation

We are focused on the discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies aimed at maintaining or improving the health and performance of muscle tissue. Our initial core product is MYO-T12, a natural, temporary myostatin-inhibiting product. Our sales are conducted pursuant to our distribution agreement with MHP. Our plan of action over the next twelve months is to: (i) deepen the scientific understanding of the activity of MYO-T12, specifically as a natural and temporary modulator of the regulatory peptide myostatin, and to leverage this knowledge to strengthen and build our intellectual property, (ii) conduct research and development activities to evaluate myostatin modulation in a range of both wellness and disease states, (iii) identify other products and technologies which may broaden our portfolio and define a business development strategy to protect, enhance and accelerate the growth of our products, (iv) reduce the cost of manufacturing through process improvement, (v) identify contract manufacturing resources that can fully meet our future growth requirements, (vi) develop a differentiated and advantaged consumer positioning, brand name and iconography, and (vii) create a sales and marketing capability through alliances to maximize near-term and future revenues. We believe that existing wellness and therapeutic targets, such as myostatin, represent a rational entry point for additional drug discovery efforts and are evaluating a separate, concurrent objective in this area.

Our distribution agreement with MHP represents a significant shift away from our previous plan to market the product to the consumer as well as to other specialty retail distributors directly. Instead, we co-brand our product under the MYO-X name and focus on conducting clinical trials of MYO-T12 to support our marketing claims as well as to enhance our intellectual property, to develop product improvements and new products, and to reduce the cost of the product by finding more efficient manufacturing processes and contract manufacturers. MHP's exclusivity expired in September 2013 and the parties are negotiating a new agreement.

As an early development-stage biotherapeutics and nutritional products company, we are dedicated to basic and clinical research which support our existing and future product portfolio. We have launched our internal research and development efforts through construction of a dedicated protein chemistry and proteomics laboratory led by Dr. Neerav Padilya. The Company incurred approximately \$49,000 of costs related to the construction of its state-of-the-art research laboratory through the third quarter of 2013 which have been capitalized for future R&D activities. This laboratory is actively evaluating the many active molecules in our lead product MYO-T12. In addition, the research performed in this laboratory will establish a basis for the continued submission of patent applications to help protect the Company's intellectual property. The Company is dedicated to protecting its innovative technology.

Additionally, the Company invests in research and development activities externally through academic and industry collaborations aimed at enhancing its products and broadening its product portfolio. The Company is committed to research and development and expects its investment in research and development to continue to grow in the future.

In July 2013, the Company entered into a clinical study agreement with The Brigham and Woman's Hospital, Inc. to conduct a clinical study on the effects of MYO-T12 alone or in combination with testosterone on skeletal mass and the fat mass in a preclinical rodent model. This study is expected to be completed in the first quarter of 2014.

In September 2013, the Company entered into a clinical study agreement with Hackensack University Medical Center to conduct a clinical study to determine the effects of MYO-T12 on blood chemistries and body mass index in healthy adult women. This study is expected to be completed in the first quarter of 2014.

This aforementioned agreements are an integral part of our business strategy and we believe they will provide a clear scientific rationale for MYO-T12's role as a nutritional product and support its use in different medical and health applications in the future.

We believe that the best use of any additional funding would be to pursue clinical studies and medical research to support differentiated and advantaged marketing claims, to build and enhance our competitive insulation via strategically based additional intellectual property, to develop product improvements and new products in consumer preferred dosage forms, to enhance overall marketing, to establish a scientific foundation for therapeutic applications for our technology, and to pursue best in class personnel.

Three Months Ended September 30, 2013 compared to Three Months Ended September 30, 2012

For the three months ended September 30, 2013, the Company generated gross revenues of \$1,019,952 (\$917,574 net of rebates) compared to gross and net revenues of \$365,934 (\$NIL rebates) for the three months ended September 30, 2012. The Company sold 25,495 cans (300 grams/can) of its product during the three months ended September 30, 2013 compared to sales of 8,927 cans (300 grams/can) of its product during the three months ended September 30, 2012. Gross profit for the three months ended September 30, 2013 was \$490,143 compared to \$11,344 for the three months ended September 30, 2012. General and administrative expenses for the three months ended September 30, 2013 was \$1,271,562 compared to \$1,058,968 for the three months ended September 30, 2012, mostly due to higher advertising costs. Other income for the three months ended September 30, 2013 was income of \$837 compared to income of \$235,046 for the three months ended September 30, 2012, mostly due to no income recorded from the

change in the fair value of our outstanding warrants during the current period. The net loss for the three months ended September 30, 2013 was \$780,582 compared to a net loss of \$812,578 for the three months ended September 30, 2012.

Research and development costs (which are included in general and administrative expenses) for the three months ended September 30, 2013 was \$112,924 compared to \$18,279 for the three months ended September 30, 2012.

Upon completion of our quarterly impairment testing for indefinite lived intangible assets after the third quarter of 2013, we determined that the carrying values of the intellectual property intangible assets did not exceed its fair value. As a result, no impairment existed and there was no change to the carrying amount of intellectual property for the three months ended September 30, 2013.

Nine Months Ended September 30, 2013 compared to Nine Months Ended September 30, 2012

For the nine months ended September 30, 2013, the Company generated gross revenues of \$2,140,595 (\$1,910,287 net of rebates) compared to gross and net revenues of \$734,363 (\$NIL rebates) for the nine months ended September 30, 2012. The Company sold 53,517 cans (300 grams/can) of its product during the nine months ended September 30, 2013 compared to sales of 17,285 cans (300 grams/can) of its product during the nine months ended September 30, 2012. Gross profit for the nine months ended September 30, 2013 was \$1,038,099 compared to \$78,366 for the nine months ended September 30, 2012. General and administrative expenses for the nine months ended September 30, 2013 was \$3,896,374 compared to \$2,091,975 for the nine months ended September 30, 2012, mostly due to higher advertising, salary and consulting costs. Other income (expense) for the nine months ended September 30, 2013 was income of \$3,959 compared to expense of (\$882,667) for the nine months ended September 30, 2012, mostly due to no interest expense during the current period. The net loss for the nine months ended September 30, 2013 was \$2,854,316 compared to a net loss of \$2,896,286 for the nine months ended September 30, 2012.

Research and development costs (which are included in general and administrative expenses) for the nine months ended September 30, 2013 was \$398,199 compared to \$18,279 for the nine months ended September 30, 2012.

Period from April 11, 2007 (Date of Inception) to September 30, 2013

In the period from April 11, 2007 (inception) to September 30, 2013, we generated gross revenues \$3,184,141 (\$2,921,489 net of rebates, including net revenues from MHP of \$2,743,759) while incurring \$11,772,539 in general and administrative expenses. The cumulative net loss since inception is \$12,500,022 including net non-cash derivatives valuation adjustments of \$1,680,267 and intellectual property impairment charges of \$2,662,000.

The Company incurred research and development costs (which are included in general and administrative expenses) in the period from April 11, 2007 (inception) to September 30, 2013 of \$605,020.

Upon completion of our annual impairment testing for indefinite-lived intangible assets after the fourth quarter of 2011, we determined that the carrying values of the intellectual property intangible assets exceeded its fair value and we recorded noncash impairment charges totaling \$2,662,000, reducing the carrying value of the asset to its fair value of \$2,000,000. Such revaluation did not affect our cash flow.

#### Liquidity and Capital Resources

The Company plans to incur approximately \$687,000 in research and development costs within the next two fiscal quarters in addition to its normal operating cash needs.

As of September 30, 2013, we had cash of \$1,883,464 and \$4,708,989 in total assets (which includes \$2,038,117 of intangible assets). For the nine months ended September 30, 2013, we used cash of \$2,096,198. We also have funds up to \$500,000 available in a line of credit (See NOTE 10 - Commitments, Contingencies and other Comments). Additionally, the Company may seek to raise additional capital through the issuance of debt or equity

securities. We believe we will have sufficient funds for operations, inventory procurement, product development and research and development costs through September 30, 2014.

#### Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that we consider material.

#### Critical Accounting Policies

##### Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes, and disclosure of contingent liabilities at the date of the financial statements. Estimates are used for, but not limited to, the selection of the useful lives of property and equipment, provisions necessary for contingent liabilities, fair values, revenue recognition, taxes, budgeted costs and other similar charges. Management believes that the estimates utilized in preparing its financial statements are reasonable and prudent. Actual results could differ from these estimates.

### Impact of Derivative Accounting

As a result of recent financing transactions we have entered into, our financial statements are impacted by the accounting effect of the application of derivative accounting. ASC Topic 815 and ASC Topic 815-40 govern the accounting treatment for both freestanding and embedded derivative financial instruments in our financial statements. Generally, warrants, conversion features in debt, and similar terms that include “full-ratchet” or reset provisions, which mean that the exercise or conversion price adjusts to pricing in subsequent sales or issuances, no longer meet the definition of indexed to a company's own stock and are not an exemption for equity classification provided in ASC Topic 815-15. The amount of non-cash gains or losses we record is based upon the fair market value of our common stock on the measurement date. The fair value of certain warrants outstanding which have “full-ratchet” or reset provisions (whereby the exercise or conversion price adjusts to pricing in subsequent sales or issuances in certain instances) is based on judgment as to the expected future volatility of our common stock.

### Long-lived Assets

We apply the provisions of Financial Accounting Standard Board (FASB) Accounting Standards Codification (ASC) No. 360, Property, Plant and Equipment. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable through the estimated undiscounted cash flows expected to result from the use and eventual disposition of the assets. Whenever any such impairment exists, an impairment loss will be recognized for the amount by which the carrying value exceeds the fair value.

We test long-lived assets, including property, plant and equipment and other assets, for recoverability at least annually or more frequently upon the occurrence of an event or when circumstances indicate that the net carrying amount is greater than its fair value. Assets are grouped and evaluated at the lowest level for their identifiable cash flows that are largely independent of the cash flows of other groups of assets. We consider historical performance and future estimated results in our evaluation of potential impairment and then compare the carrying amount of the asset to the future estimated cash flows expected to result from the use of the asset. If the carrying amount of the asset exceeds estimated expected undiscounted future cash flows, we measure the amount of impairment by comparing the carrying amount of the asset to its fair value. The estimation of fair value is generally measured by discounting expected future cash flows as the rate we utilize to evaluate potential investments. We estimate fair value based on the information available in making the necessary estimates, judgments and projections.

### Fair Value of Indefinite-Lived Intangible Assets

Our policy is to evaluate indefinite-lived intangible assets for possible impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An intangible asset with an indefinite life (the intellectual property) is evaluated for possible impairment by comparing the fair value of the asset with its carrying value. Fair value is estimated as the discounted value of future revenues arising from a trademark using a royalty rate that an independent party would pay for use of that trademark. An impairment charge is recorded if the trademark's carrying value exceeds its estimated fair value. An impairment charge is recorded if the carrying value of the goodwill exceeds its implied fair value. See Note 8 - Intellectual Property Purchase Agreement for information related to impairment charges recorded in 2011 for indefinite-lived intellectual property intangible assets.

### Equity Based Compensation

We account for equity-based compensation under the provisions of ASC 718-10 Compensation - Stock Compensation and ASC 505-50 Equity Based Payments to Non-Employees. ASC 718 requires companies to estimate the fair value

of share-based payment awards on the date of grant using an option-pricing model. For stock options and restricted stock that do not vest immediately but which contain only a service vesting feature, we recognize compensation cost on the unvested shares and options on a straight-line basis over the remaining vesting period, net of any projected forfeitures.

We use the Black-Scholes option-pricing model as our method of valuation for share-based compensation. Our determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to our expected stock price volatility over the term of the awards, and certain other market variables such as the risk free interest rate.

#### Income Taxes

We account for income taxes using an asset and liability approach which allows for the recognition and measurement of deferred tax assets based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will either expire before we are able to realize their benefits, or that future deductibility is uncertain.

We record a valuation allowance for deferred tax assets, if any, based on our estimates of future taxable income as well as tax planning strategies when it is more likely than not that a portion or all of its deferred tax assets will not be realized. If we are able to utilize more of our deferred tax assets than the net amount previously recorded when unanticipated events occur, an adjustment to deferred tax assets would increase our net income when those events occur.

Item Quantitative and Qualitative Disclosures About Market Risk.

3.

We are a smaller reporting company and therefore, we are not required to provide information required by this Item of Form 10-Q.

Item Controls and Procedures.

4.

Evaluation of Disclosure Controls and Procedures

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) that is designed to ensure that information we are required to disclose in the reports that we file or submit under the Exchange Act are recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms. Disclosure controls and procedure include, without limitations, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

In accordance with Exchange Act Rules 13a-15 and 15d-15, an evaluation was completed by our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2013. Based on that evaluation, these officers concluded that our disclosure controls and procedures were effective in providing reasonable assurance that the information required to be disclosed in our reports filed or submitted under the Exchange Act for the quarter ended September 30, 2013 was recorded, processed, summarized, and reported within the time periods specified in the Commission's rules and forms.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the quarter ended September 30, 2013 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## PART II-OTHER INFORMATION

Item 1. Legal Proceedings.

None.

Item 1A. Risk Factors.

Factors that could cause our actual results to differ materially from those in this report are any of the risks described in our Annual Report on Form 10-K for the year ended December 31, 2012 filed with the SEC. Any of these factors

could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations.

As of the date of this report, except as set forth below, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2012 filed with the SEC, except we may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None

25

---

Item 3. Defaults Upon Senior Securities.

None

Item 4. Mine Safety Disclosures.

None

Item 5. Other Information.

None

Item 6. Exhibits.

No.	Description
31.1	Certification of Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.CAL *	XBRL Taxonomy Extension Calculation Linkbase Document
101.SCH *	XBRL Taxonomy Extension Schema Document
101.DEF *	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB *	XBRL Taxonomy Extension Labels Linkbase Document
101.PRE *	XBRL Taxonomy Extension Presentation Linkbase Document

\* XBRL (eXtensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MYOS CORPORATION

Date: November 8, 2013

By: /s/ Carl DeFreitas  
Name: Carl DeFreitas  
Title: Chief Financial Officer